Cargando…

PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer

Protease activated receptor-1 (PAR1) expression is associated with disease progression and overall survival in a variety of cancers. However, the importance of tumor cell PAR1 in pancreatic ductal adenocarcinomas (PDAC) remains unexplored. Utilizing orthotopic models with wild type and PAR1-targeted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tekin, Cansu, Shi, Kun, Daalhuisen, Joost B., ten Brink, Marieke S., Bijlsma, Maarten F., Spek, C. Arnold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112838/ https://www.ncbi.nlm.nih.gov/pubmed/30174793 http://dx.doi.org/10.18632/oncotarget.25880

Ejemplares similares

Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis
por: Lin, Cong, et al.
Publicado: (2015)

Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation
por: Tekin, Cansu, et al.
Publicado: (2020)

Protease‐activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma
por: Tekin, Cansu, et al.
Publicado: (2021)

Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion
por: Tekin, Cansu, et al.
Publicado: (2020)

Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?
por: Slapak, Etienne J., et al.
Publicado: (2020)

Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer
por: Slapak, Etienne J., et al.
Publicado: (2023)

Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation
por: Duitman, JanWillem, et al.
Publicado: (2021)

Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview
por: Slapak, Etienne J., et al.
Publicado: (2022)

Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors
por: Hindriksen, Sanne, et al.
Publicado: (2012)

CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells
por: Hartl, Leonie, et al.
Publicado: (2020)

ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer
por: Slapak, Etienne J., et al.
Publicado: (2021)

PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?
por: Spek, C. Arnold, et al.
Publicado: (2023)

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer
por: Lin, Cong, et al.
Publicado: (2017)

The contributions of hypoxia to poor outcomes in pancreatic cancer
por: Bijlsma, Maarten F.
Publicado: (2022)

High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1
por: Steins, Anne, et al.
Publicado: (2020)

Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations
por: Mpilla, Gabriel Benyomo, et al.
Publicado: (2020)

The case for a stratified application of targeted agents against pancreatic cancer
por: Bijlsma, Maarten F.
Publicado: (2021)

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
por: Houg, Demi S., et al.
Publicado: (2018)

uPAR: An Essential Factor for Tumor Development
por: Lv, Tao, et al.
Publicado: (2021)

Repression of Smoothened by Patched-Dependent (Pro-)Vitamin D3 Secretion
por: Bijlsma, Maarten F, et al.
Publicado: (2006)

C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC
por: Hartl, Leonie, et al.
Publicado: (2023)

Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors
por: Vaziri-Gohar, Ali, et al.
Publicado: (2022)

Phosphorylation of IWS1 by AKT maintains liposarcoma tumor heterogeneity through preservation of cancer stem cell phenotypes and mesenchymal-epithelial plasticity
por: Wang, Yu, et al.
Publicado: (2023)

Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis
por: Rao, J S, et al.
Publicado: (2013)

Chemoresistance and the Self-Maintaining Tumor Microenvironment
por: Yeldag, Gulcen, et al.
Publicado: (2018)

Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
por: Bijlsma, Maarten F., et al.
Publicado: (2022)

The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth
por: Manoukian, Paul, et al.
Publicado: (2021)

RGS5 maintaining vascular homeostasis is altered by the tumor microenvironment
por: Kong, Peng, et al.
Publicado: (2023)

Doxycycline directly targets PAR1 to suppress tumor progression
por: Zhong, Weilong, et al.
Publicado: (2017)

The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi
por: Hovius, Joppe W. R., et al.
Publicado: (2009)

Local irradiation of patient-derived tumors in immunodeficient mice
por: van der Zalm, Amber P., et al.
Publicado: (2023)

Epithelial-Mesenchymal Transition Is a Critical Step in Tumorgenesis of Pancreatic Neuroendocrine Tumors
por: Fendrich, Volker, et al.
Publicado: (2012)

CDC20 maintains tumor initiating cells
por: Xie, Qi, et al.
Publicado: (2015)

Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity
por: van Neerven, Sanne M., et al.
Publicado: (2015)

Tissue amino acid profiles are characteristic of tumor type, malignant phenotype, and tumor progression in pancreatic tumors
por: Hiraoka, Nobuyoshi, et al.
Publicado: (2019)

Nanotopography reveals metabolites that maintain the immunomodulatory phenotype of mesenchymal stromal cells
por: Ross, Ewan A., et al.
Publicado: (2023)

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone
por: Moore, Z, et al.
Publicado: (2015)

Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma
por: Strijker, Marin, et al.
Publicado: (2019)

Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor Budding the Missing Link?
por: Karamitopoulou, Eva
Publicado: (2013)

Mesenchymal Stem Cells Promote Pancreatic Tumor Growth by Inducing Alternative Polarization of Macrophages()()
por: Mathew, Esha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_blgp2a3sns5t56bc9q9efueifg